Loading...
MSN Laboratories Private Limited — Carfilzomib Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #1 for Carfilzomib · $90.9K export value · DGFT Verified
MSN Laboratories Private Limited is the #1 Indian exporter of Carfilzomib with $90.9K in export value and 19 verified shipments. MSN Laboratories Private Limited holds a 7.5% market share in Carfilzomib exports across 4 countries. The company exports 32 pharmaceutical products worth $252.1M across 15 therapeutic categories.
MSN Laboratories Private Limited exports Carfilzomib to 4 countries. The largest destination is CHILE accounting for 97.7% of MSN Laboratories Private Limited's Carfilzomib shipments, followed by BRAZIL (2.3%) and UNITED STATES (0.0%). These destinations reflect MSN Laboratories Private Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MSN LABS CHILE SPARUT | CHILE | $50.0K | 1 |
| MSN LABS BRASIL LTDA | BRAZIL | $484 | 3 |
| SAFE LAB LOGISTICS SAFELAB TRANSPORTES LIMITED A RUA | BRAZIL | $253 | 4 |
| SANDOZ DO BRASIL INDUSTRIA FARMACEUTICA AS T DEPARTMENT RUA | BRAZIL | $240 | 1 |
| SANDOZ DO BRASIL INDUSTRIA | BRAZIL | $158 | 2 |
| SANDOZ DO BRASIL INDUSTRIA FARMACE | BRAZIL | $47 |
India exported $261.8K worth of Carfilzomib through 203 shipments from 65 suppliers to 47 countries, serving 105 buyers globally. MSN Laboratories Private Limited contributes $90.9K to this total, accounting for 7.5% of India's Carfilzomib exports. MSN Laboratories Private Limited ships Carfilzomib to 4 countries through 9 buyers.
MSN Laboratories Private Limited's average Carfilzomib shipment value is $4.8K per consignment, based on 19 shipments totaling $90.9K. The largest destination is CHILE (97.7% of MSN Laboratories Private Limited's Carfilzomib exports).
MSN Laboratories Private Limited ranks #1 among 65 Indian Carfilzomib exporters with a 7.5% market share. The top 3 exporters are MSN LABORATORIES PRIVATE LIMITED ($90.9K), SARTAJ PHARMA PRIVATE LIMITED ($32.9K), NATCO PHARMA LIMITED ($31.8K). MSN Laboratories Private Limited processed 19 shipments to 4 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| MSN FORMULATIONS PRODUCT: XOMICIB 60MGCARFILZOMIB FOR INJECTION 60 MG/VIAL1X1'S PACK 40 NO'S OF FREE SAMPLES | $50.0K | 1 |
| MSN PHARMACEUTICAL PRODUCT NAME: PLACEBOFOR CARFILZOMIB | $240 | 1 |
| MSN PHARMACEUTICAL PRODUCT NAME: CARFILZOMIB FOR INJECTION 60MG/ VIAL | $229 | 2 |
| CARFILZOMIB FOR INJ 60MG/VIAL | $200 | 2 |
| CARFILZOMIB FOR INJECTION 60MG/VIAL | $147 | 1 |
| PLACEBO FOR CARFILZOMIB FOR INJECTION V | $137 | 1 |
| PLACEBO FOR CARFILZOMIB FOR INJECTION(QTY:0.002 PAC)(SAMPLES FOR TESTING PURPOSEONLY) | $116 | 1 |
| PLACEBO FOR CARFILZOMIB FOR INJECTION 60MG VIAL QTY 120 NOS TESTING PURPOSE ONLY | $47 | 2 |
What MSN Laboratories Private Limited must comply with to export Carfilzomib to its top destination countries
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | MSN LABORATORIES PRIVATE LIMITED ★ | $90.9K | 19 | 4 | $4.8K |
| 2 | SARTAJ PHARMA PRIVATE LIMITED | $32.9K | 7 | 3 | $4.7K |
| 3 | NATCO PHARMA LIMITED | $31.8K | 7 | 2 | $4.5K |
MSN Laboratories Private Limited ranks #1 among 65 Indian Carfilzomib exporters. Average shipment value of $4.8K compared to the market average of $4.0K. The closest competitors by value are SARTAJ PHARMA PRIVATE LIMITED and NATCO PHARMA LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 38 | 18.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 32 | 15.8% |
| DELHI AIR | 26 | 12.8% |
| HYDERABAD ACC (INHYD4) | 19 | 9.4% |
| Bombay Air | 19 | 9.4% |
| DELHI AIR CARGO ACC (INDEL4) | 9 | 4.4% |
| HYDERABAD AIR | 9 | 4.4% |
| Bombay Air Cargo | 9 | 4.4% |
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like MSN Laboratories. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major shipping lines to alter routes. This has resulted in extended transit times by 10–20 days and a 40–50% increase in freight rates on key India–Europe routes, impacting the timely delivery of pharmaceutical products. (livemint.com)
Conversely, the ongoing US-China trade tensions have prompted the United States to diversify its pharmaceutical supply chain, potentially benefiting Indian exporters. However, the imposition of tariffs on Indian pharmaceutical products poses a risk to export volumes, as higher tariffs can lead to increased costs and reduced competitiveness in the US market. (orfonline.org)
In the European Union, compliance with the Falsified Medicines Directive (FMD) requires stringent serialization and traceability measures. For companies like MSN Laboratories, adhering to these regulations is crucial to maintain market access and ensure the integrity of their supply chain.
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA), World Health Organization (WHO), and European Union Good Manufacturing Practice (EU GMP) guidelines set rigorous quality benchmarks. Any lapses can lead to import bans, product recalls, and reputational damage.
MSN Laboratories' recent legal challenges, such as the patent litigation with Exelixis, Inc., highlight the importance of robust regulatory and intellectual property strategies. Ensuring compliance with evolving quality requirements and proactively addressing regulatory challenges are essential for sustaining export growth and market credibility.
MSN Laboratories Private Limited exports 32 products worth $252.1M. Beyond Carfilzomib, top products include Atorvastatin, Rosuvastatin, Ras, Oseltamivir, Calcium. View the complete MSN Laboratories Private Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Carfilzomib — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for MSN Laboratories Private Limited's Carfilzomib exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
MSN Laboratories Private Limited
Full Company Profile →
32 products · $252.1M total trade · 15 categories
| 2 |
| NANOTECH PHARMA | UNITED STATES | $0 | 3 |
| MR. CAIHAIHAI, | CHINA | $0 | 2 |
| MSN LABS BRASIL LIMITEDA | BRAZIL | $0 | 1 |
MSN Laboratories Private Limited supplies Carfilzomib to 9 buyers globally. The largest buyer is MSN LABS CHILE SPARUT (CHILE), followed by MSN LABS BRASIL LTDA (BRAZIL) and SAFE LAB LOGISTICS SAFELAB TRANSPORTES LIMITED A RUA (BRAZIL). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| CARFILZOMIB FOR INJECTION 60 MG/VIAL(QTY:250 PAC)(SAMPLES FOR TESTING PURPOSE ONLY) | $42 | 1 |
| MSN PHARMACEUTICAL PRODUCT NAME: PLACEBOFOR CARFILZOMIB FOR INJECTION 60MG/VIAL | $24 | 2 |
MSN Laboratories Private Limited exports 15 distinct Carfilzomib formulations including tablets, capsules, syrups, and combination drugs. The top formulation is MSN FORMULATIONS PRODUCT: XOMICIB 60MGCARFILZOMIB FOR INJECT with 1 shipments worth $50.0K.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 47+ countries, 105+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for MSN Laboratories Private Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Carfilzomib. For current shipment-level data, contact TransData Nexus.